Background

Recently, with the rising popularity of wellness trends, peptides have gained significant attention, particularly on social media. Influencers and celebrities have promoted specific peptides for wound healing, anti-aging, and muscle enhancement, leading to increased public interest. However, these substances are not approved drugs but rather research chemicals, and they have been distributed through unregulated online channels. This poses health risks as consumers may be exposed to unknown ingredients from unregulated manufacturers. Consequently, there have been calls to include these peptides in the list of compounding pharmacy ingredients to ensure quality control within the regulated system. In contrast, scientists at the U.S. Food and Drug Administration (FDA) have strongly warned against relaxing regulations, citing the lack of clinical trial data to support their safety and efficacy. Peptides are structurally prone to degradation, and when administered as injections, they carry a high risk of causing severe infections, such as sepsis, if contaminated.

Key Findings

From July 23rd to 24th, the FDA's Pharmacy Compounding Advisory Committee (PCAC) held a meeting to review a total of seven peptide compounds. The committee agreed to recommend adding six of these compounds – BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax – to the 503A bulk list, which is the list of ingredients used for compounding pharmacy preparations. However, the addition of emideltide, which is associated with sleep disorders, was not approved. This vote is notable because it directly contradicts the recommendations of FDA's internal scientists. In a report submitted to the advisory committee, FDA staff pointed out that these peptides have not undergone proper clinical trials in humans and that the available data is limited to basic research, raising concerns about potential serious adverse effects. Specifically, the report highlighted concerns about hepatotoxicity and reproductive toxicity associated with BPC-157, and the lack of conclusive clinical data to support the efficacy of the other compounds. However, the advisory committee members emphasized that consumers are already purchasing these compounds from unregulated online sources. They believe that providing a legal pathway through compounding pharmacies would ensure adherence to quality standards and improve transparency in the supply chain. As a result, the advisory committee passed the recommendation to include these six peptides in the bulk list by a majority vote.

Significance and Outlook

The advisory committee's vote is only a recommendation, and the FDA is not obligated to accept it. However, given the political climate, including the stance of Robert F. Kennedy Jr., the Secretary of the Department of Health and Human Services (HHS), who supports expanding patient access to treatment, it is likely that the FDA will face significant pressure. Even if the FDA ultimately accepts this recommendation, it will take some time before legal compounding can begin in pharmacies, as it requires the completion of formal administrative rulemaking procedures. This includes publishing the list in the Federal Register and soliciting public comments. The scientific community remains concerned. There are concerns that allowing the legal distribution of unproven substances could lead to misuse and unforeseen health consequences. Furthermore, there are concerns that scientific data should be the primary basis for regulatory decisions, but that political demands and public opinion may undermine this principle. The global bio and pharmaceutical industries are closely watching to see whether the FDA will adopt the advisory committee's recommendations or uphold scientific principles and exercise its veto power.